Phosphate: a stealthier killer than previously thought?

[1]  J. Navarro-González,et al.  Expression of FGF23/KLOTHO system in human vascular tissue. , 2013, International journal of cardiology.

[2]  D. Tanné,et al.  Cerebral artery calcification in patients with acute cerebrovascular diseases: determinants and long‐term clinical outcome , 2012, European journal of neurology.

[3]  T. Chico,et al.  Phosphate: the new cholesterol? The role of the phosphate axis in non-uremic vascular disease. , 2012, Atherosclerosis.

[4]  Z. Massy,et al.  Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  A. Go,et al.  FGF23 induces left ventricular hypertrophy. , 2011, The Journal of clinical investigation.

[6]  C. Shanahan,et al.  Arterial Calcification in Chronic Kidney Disease: Key Roles for Calcium and Phosphate , 2011, Circulation research.

[7]  R. Eastell,et al.  Dietary Phosphate Modulates Atherogenesis and Insulin Resistance in Apolipoprotein E Knockout Mice—Brief Report , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[8]  M. Ketteler,et al.  Mechanisms and treatment of extraosseous calcification in chronic kidney disease , 2011, Nature Reviews Nephrology.

[9]  A. Ortiz,et al.  Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  Huiliang Xie,et al.  Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. , 2011, Kidney international.

[11]  L. Schurgers,et al.  Microcalcifications in early intimal lesions of atherosclerotic human coronary arteries. , 2011, The American journal of pathology.

[12]  P. D’Haese,et al.  Cell biological and physicochemical aspects of arterial calcification. , 2011, Kidney international.

[13]  S. Moebus,et al.  Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. , 2011, Journal of the American College of Cardiology.

[14]  A. Hayen,et al.  Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. , 2011, JAMA.

[15]  M. Budoff,et al.  Mortality in individuals without known coronary artery disease but with discordance between the Framingham risk score and coronary artery calcium. , 2011, The American journal of cardiology.

[16]  D. Bowden,et al.  Coronary Calcium Score and Prediction of All-Cause Mortality in Diabetes , 2011, Diabetes Care.

[17]  A. Werner,et al.  Phosphate transporters in renal, gastrointestinal, and other tissues. , 2011, Advances in chronic kidney disease.

[18]  M. Wolf,et al.  Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  E. Neven,et al.  Vascular Calcification in Chronic Renal Failure: What Have We Learned From Animal Studies? , 2011, Circulation research.

[20]  Zahi A Fayad,et al.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2010, Circulation.

[21]  W. C. O'Neill,et al.  Recent progress in the treatment of vascular calcification. , 2010, Kidney international.

[22]  K. Ozono,et al.  Both FGF23 and extracellular phosphate activate Raf/MEK/ERK pathway via FGF receptors in HEK293 cells , 2010, Journal of cellular biochemistry.

[23]  Daniel S Berman,et al.  Progression of coronary artery calcium predicts all-cause mortality. , 2010, JACC. Cardiovascular imaging.

[24]  M. Shibuya,et al.  Klotho is associated with VEGF receptor-2 and the transient receptor potential canonical-1 Ca2+ channel to maintain endothelial integrity , 2010, Proceedings of the National Academy of Sciences.

[25]  M. Kanbay,et al.  Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[26]  S. Srinivasan,et al.  Relation of serum phosphorus levels to carotid intima-media thickness in asymptomatic young adults (from the Bogalusa Heart Study). , 2010, The American journal of cardiology.

[27]  M. Wolf,et al.  Forging forward with 10 burning questions on FGF23 in kidney disease. , 2010, Journal of the American Society of Nephrology : JASN.

[28]  M. Ohnishi,et al.  Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  A. Ortiz,et al.  The expanding spectrum of biological actions of vitamin D. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  K. Rosenblatt,et al.  Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  M. Chonchol,et al.  Relation of serum phosphorus levels to ankle brachial pressure index (from the Third National Health and Nutrition Examination Survey). , 2010, The American journal of cardiology.

[32]  J. Bax,et al.  Elevated Preoperative Phosphorus Levels Are an Independent Risk Factor for Cardiovascular Mortality , 2010, American Journal of Nephrology.

[33]  W. März,et al.  Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. , 2010, European heart journal.

[34]  C. Gieger,et al.  Common genetic variants associate with serum phosphorus concentration. , 2010, Journal of the American Society of Nephrology : JASN.

[35]  D. Vanderschueren,et al.  Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[36]  L. Schurgers,et al.  The Associations of Fibroblast Growth Factor 23 and Uncarboxylated Matrix Gla Protein With Mortality in Coronary Artery Disease: The Heart and Soul Study , 2010, Annals of Internal Medicine.

[37]  T. Larsson.  The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[38]  Florian Kronenberg,et al.  Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[39]  S. Cummings,et al.  Serum phosphorus levels and the spectrum of ankle-brachial index in older men: the Osteoporotic Fractures in Men (MrOS) study. , 2010, American journal of epidemiology.

[40]  M. Tonelli,et al.  Oral phosphate binders in patients with kidney failure. , 2010, The New England journal of medicine.

[41]  K. Kalantar-Zadeh,et al.  Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[42]  A. Lorenzo,et al.  The effects of Italian Mediterranean organic diet (IMOD) on health status. , 2010, Current pharmaceutical design.

[43]  V. Jorgetti,et al.  Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[44]  Satoko Nakamura,et al.  Coronary calcification in patients with chronic kidney disease and coronary artery disease. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[45]  M. Razzaque,et al.  In Vivo Genetic Evidence for Suppressing Vascular and Soft-Tissue Calcification Through the Reduction of Serum Phosphate Levels, Even in the Presence of High Serum Calcium and 1,25-Dihydroxyvitamin D Levels , 2009, Circulation. Cardiovascular genetics.

[46]  N. Powe,et al.  Peripheral vascular disease-related procedures in dialysis patients: predictors and prognosis. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[47]  M. Wolf,et al.  A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. , 2009, Kidney international.

[48]  J. Navarro-González,et al.  Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[49]  A. Ortiz,et al.  Alkalinization potentiates vascular calcium deposition in an uremic milieu. , 2009, Journal of nephrology.

[50]  C. Chazot,et al.  High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[51]  Y. Nakaya,et al.  Dietary phosphorus acutely impairs endothelial function. , 2009, Journal of the American Society of Nephrology : JASN.

[52]  C. Reutelingsperger,et al.  Fetuin-A protects against atherosclerotic calcification in CKD. , 2009, Journal of the American Society of Nephrology : JASN.

[53]  C. Giachelli.  The emerging role of phosphate in vascular calcification. , 2009, Kidney international.

[54]  M. Chonchol,et al.  Serum phosphorus and cardiovascular mortality in type 2 diabetes. , 2009, The American journal of medicine.

[55]  T. Okada,et al.  Regulation of Fibroblast Growth Factor 23 Production in Bone in Uremic Rats , 2009, Nephron Physiology.

[56]  B. Kestenbaum,et al.  Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[57]  B. Kestenbaum,et al.  Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III). , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[58]  M. Wolf,et al.  Phosphorus binders and survival on hemodialysis. , 2009, Journal of the American Society of Nephrology : JASN.

[59]  B. Kestenbaum,et al.  Association of serum phosphate with vascular and valvular calcification in moderate CKD. , 2009, Journal of the American Society of Nephrology : JASN.

[60]  M. Tokumoto,et al.  Blockage of the Renin-Angiotensin System Attenuates Mortality but Not Vascular Calcification in Uremic Rats: Sevelamer Carbonate Prevents Vascular Calcification , 2009, American Journal of Nephrology.

[61]  A. Ortiz,et al.  Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients. , 2008, Kidney international. Supplement.

[62]  R. Foley,et al.  Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. , 2008, American heart journal.

[63]  P. Kerr,et al.  Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[64]  M. Wolf,et al.  Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. , 2008, The New England journal of medicine.

[65]  Suresh Mathew,et al.  Hyperphosphatemia of chronic kidney disease. , 2008, Kidney international.

[66]  Stefan Pilz,et al.  Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. , 2008, Archives of internal medicine.

[67]  M. Wolf,et al.  Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. , 2008, Journal of the American Society of Nephrology.

[68]  W. Suki,et al.  Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. , 2007, Kidney international.

[69]  L. Shaw,et al.  Phosphorus levels are associated with subclinical atherosclerosis in the general population. , 2007, Atherosclerosis.

[70]  S. Takeda,et al.  Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans , 2007, Journal of Bone and Mineral Metabolism.

[71]  G. Åkerström,et al.  Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. , 2007, The Journal of endocrinology.

[72]  F. Kronenberg,et al.  Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. , 2007, Journal of the American Society of Nephrology : JASN.

[73]  R. D'Agostino,et al.  Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. , 2007, Archives of internal medicine.

[74]  G. London,et al.  Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. , 2007, Journal of the American Society of Nephrology : JASN.

[75]  K. Okawa,et al.  Klotho converts canonical FGF receptor into a specific receptor for FGF23 , 2006, Nature.

[76]  E. Shuto,et al.  Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. , 2006, Kidney international.

[77]  S. Moe.  Vascular calcification and renal osteodystrophy relationship in chronic kidney disease , 2006, European journal of clinical investigation.

[78]  K. Kalantar-Zadeh,et al.  Association of disorders in mineral metabolism with progression of chronic kidney disease. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[79]  Z. Massy,et al.  Sevelamer Prevents Uremia-Enhanced Atherosclerosis Progression in Apolipoprotein E–Deficient Mice , 2005, Circulation.

[80]  M. Pfeffer,et al.  Relation Between Serum Phosphate Level and Cardiovascular Event Rate in People With Coronary Disease , 2005, Circulation.

[81]  A. Go,et al.  Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. , 2005, Journal of the American Society of Nephrology : JASN.

[82]  M. Wolf,et al.  Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[83]  M. McKee,et al.  Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. , 2005, Genes & development.

[84]  R. Rizzoli,et al.  Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. , 2005, The Journal of clinical endocrinology and metabolism.

[85]  L. Schurgers,et al.  Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. , 2004, Journal of the American Society of Nephrology : JASN.

[86]  J. Floege,et al.  Vascular calcification in patients with end-stage renal disease. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[87]  G. Chertow,et al.  Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. , 2004, Journal of the American Society of Nephrology : JASN.

[88]  D. Arking,et al.  KLOTHO allele status and the risk of early-onset occult coronary artery disease. , 2003, American journal of human genetics.

[89]  K. Miyamoto,et al.  Human Fibroblast Growth Factor-23 Mutants Suppress Na+-dependent Phosphate Co-transport Activity and 1α,25-Dihydroxyvitamin D3 Production* , 2003, The Journal of Biological Chemistry.

[90]  P. Raggi,et al.  Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. , 2002, Kidney international.

[91]  Y. Nabeshima,et al.  The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. , 2001, The Journal of nutrition.

[92]  S. Friedman,et al.  Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor. , 2001, American journal of physiology. Endocrinology and metabolism.

[93]  M. McKee,et al.  Phosphate regulation of vascular smooth muscle cell calcification. , 2000, Circulation research.

[94]  K. Watson,et al.  Active serum vitamin D levels are inversely correlated with coronary calcification. , 1997, Circulation.

[95]  R. M. Culpepper,et al.  Biochemical effects of oral sodium phosphate , 1995, Digestive Diseases and Sciences.

[96]  F. H. Tyler,et al.  Circadian rhythm in serum parathyroid hormone concentration in human subjects: correlation with serum calcium, phosphate, albumin, and growth hormone levels. , 1972, The Journal of clinical investigation.

[97]  M. Budoff,et al.  Is coronary artery calcium the key to assessment of cardiovascular risk in asymptomatic adults? , 2011, Journal of cardiovascular computed tomography.

[98]  B. Kestenbaum,et al.  Comparative effectiveness of calcium-containing phosphate binders in incident U.S. dialysis patients. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[99]  M. Kuro-o,et al.  Klotho deficiency causes vascular calcification in chronic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.

[100]  Á. D. de Francisco,et al.  Prevalence of chronic renal disease in Spain: results of the EPIRCE study. , 2010, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.